Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 5,844 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman sold 5,844 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares of the company’s stock, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Charles Gorman also recently made the following trade(s):

• On Monday, February 10th, Kevin Charles Gorman sold 2,274 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $118.37, for a total transaction of $269,173.38.
• On Friday, January 31st, Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44.
• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $115.02 on Friday. The firm has a market cap of $11.65 billion, a PE ratio of 34.96 and a beta of 0.33. The firm has a fifty day moving average of $138.09 and a 200 day moving average of $130.82. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on NBIX shares. Piper Sandler restated an “overweight” rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Deutsche Bank Aktiengesellschaft started coverage on shares of Neurocrine Biosciences in a research note on Tuesday. They set a “hold” rating and a $138.00 price objective for the company. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 10th. Canaccord Genuity Group cut their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Royal Bank of Canada cut their target price on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $166.90.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently modified their holdings of NBIX. Cetera Investment Advisers grew its holdings in shares of Neurocrine Biosciences by 7.9% during the second quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock worth $979,000 after buying an additional 519 shares in the last quarter. CWM LLC grew its holdings in shares of Neurocrine Biosciences by 15.1% during the third quarter. CWM LLC now owns 7,884 shares of the company’s stock worth $908,000 after buying an additional 1,035 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Neurocrine Biosciences by 29.3% during the third quarter. Exchange Traded Concepts LLC now owns 7,964 shares of the company’s stock worth $918,000 after buying an additional 1,803 shares in the last quarter. Creative Planning boosted its position in shares of Neurocrine Biosciences by 12.3% during the 3rd quarter. Creative Planning now owns 12,999 shares of the company’s stock valued at $1,498,000 after acquiring an additional 1,426 shares during the last quarter. Finally, Vontobel Holding Ltd. boosted its position in shares of Neurocrine Biosciences by 12.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 14,590 shares of the company’s stock valued at $1,681,000 after acquiring an additional 1,639 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.